| Literature DB >> 29935298 |
Yi Yang1, Anna Mah2, Inn H Yuk3, Parbir S Grewal3, Abigail Pynn3, Will Cole2, Di Gao2, Fan Zhang4, Jia Chen2, Lynn Gennaro2, Christian Schöneich5.
Abstract
Protein carbonylation is a posttranslational modification referring to the occurrence of aldehydes and ketones in proteins. The current understanding of how carbonylation, in particular, metal-catalyzed carbonylation, occurs in recombinant mAbs during production and storage is very limited. To facilitate investigations into mAb carbonylation, we developed a protein carbonylation assay with improved assay robustness and precision over the conventional assays. We applied this assay to investigate mAb carbonylation under production, storage, and stress conditions and showed that iron, hydrogen peroxide, and polysorbate 20 at pharmaceutically relevant levels critically influence the extent of mAb carbonylation. In addition, we found that while carbonylation correlates with mAb aggregation in several cases, carbonylation cannot be used as a general indicator for aggregation. Furthermore, we observed that mAb carbonylation level can decrease during storage, which indicates that carbonylation products may not be stable. Finally, we report for the first time a positive correlation between carbonylation and acidic charge heterogeneity of mAbs that underwent metal-catalyzed oxidation. This finding shows that the impact of protein carbonylation on product quality for mAbs is not limited to aggregation but also extends to charge heterogeneity.Entities:
Keywords: Lucifer yellow carbohydrazide (LY CH); acidic charge variants; aggregation; charge heterogeneity; metal-catalyzed oxidation; protein carbonylation; quality attributes; recombinant mAb
Mesh:
Substances:
Year: 2018 PMID: 29935298 DOI: 10.1016/j.xphs.2018.06.015
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534